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Abstract
Objectives: To compare the outcomes of sickle cell disease patients diagnosed through neonatal screening with those who were not.
Methods: In an observational multicenter study in Belgium, 167 screened and 93 unscreened sickle cell disease patients were
analyzed for a total of 1116 and 958 patient-years of follow-up, respectively. Both groups were compared with propensity score
analysis, with patients matched on three covariates (gender, genotype, and central Africa origin). Bonferroni correction was
applied for all comparisons.
Results: Kaplan–Meier estimates of survival without bacteremia were significantly higher in the screened group than the
unscreened group (94.47%; [95% CI, 88.64–97.36%] versus 83.78% [95% CI, 72.27–90.42%]), p¼ 0.032. Non-significant differ-
ences between both groups were reported for survival without acute chest syndrome, acute anemia, cerebral complication,
severe infection, and vaso-occlusive crisis. Significantly lower hospitalization rate and days per 100 patient-years were observed
in the screened compared with the unscreened group (0.27 vs. 0.63 and 1.25 vs. 2.82, p¼ 0.0006 and <0.0001).
Conclusion: These data confirm the benefit of a neonatal screening programme in reducing bacteremia and hospitalization.
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Introduction
Sickle cell disease (SCD) is the most common monogenic
hemoglobinopathy worldwide, accounting for around
300,000 new cases each year.1,2 In Europe it has received
less attention than elsewhere, but with demographic
changes, the European incidence of SCD is increasing,
and services must be planned accordingly. The introduc-
tion of neonatal screening was based on the ﬁnding that
daily oral prophylactic penicillin from age 4 months gave
an 84% risk reduction of Streptococcus pneumoniae bac-
teremia.3 Screening programmes include prophylactic
penicillin and anti-pneumococcal vaccination, parental
education to avoid the most threatening SCD-related
adverse events, and prevention of stroke using transcra-
nial Doppler ultrasound. Until now, no randomized clin-
ical trial has been conducted to evaluate the eﬃcacy of
neonatal SCD screening. Presumed eﬃcacy is based on
the mortality reduction demonstrated, particularly for
infants under age 4 years.4,5 The Belgian national neonatal
screening programme does not include SCD screening, but
local initiatives to implement SCD screening have existed
for over a decade, and a database including the diagnosis
period (i.e. at birth by neonatal screening or not) and
patients outcomes was created in 2008.6,7 This study
aimed to compare clinical outcome in two cohorts of
SCD patients born in Belgium, the ﬁrst diagnosed at
birth who beneﬁted from the screening programme, and
the latter who were unscreened.
1Hemato-Oncology, Hopital Universitaire des Enfants Reine Fabiola,
Brussels, Belgium
2Hemato-Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
3Pediatrics, Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium
4Laboratory of Hematology and Hemostasis, Centre Hospitalier
Universitaire de Brugmann, Brussels, Belgium
5Clinical Chemistry, Erasme Hospital, Brussels, Belgium
6Clinical Chemistry, Centre Hospitalier Regional de la Citadelle, Belgium
7Hemato-Oncology, Centre Hospitalier Regional de la Citadelle, Belgium
8Independant Biostatistician – Ars Statistica, Belgium
Corresponding author:
Phu Quoc Leˆ, Department of Hemato-Oncology, Hoˆpital Universitaire des











This observational study of two cohorts of patients, diag-
nosed at birth or later in life, included subjects with severe
(HbSS and HbSb0) and mild (HbSC, HbSD and HbSbþ)
genotypes. The Belgian national SCD database was estab-
lished in October 2008, with hematologists invited to
register their patients on a voluntary basis. The registry
currently includes patients from six adult and two pediat-
ric centers, of which two are secondary and six are tertiary
university care centers. Results published in 20088 esti-
mated that about 75–80% of SCD patients living in
Belgium were enrolled. Patient data before 2008 were
retrieved from medical charts and retrospectively encoded
in the database. After 2008, data were prospectively
entered in the database for all registered patients and for
newly diagnosed subjects. Data were recorded from birth
for patients diagnosed through the neonatal screening
programme, or from diagnosis following the ﬁrst contact
in the participating center, and until last follow-up visit, or
death. Universal neonatal screening was progressively
implemented in Brussels from 1994, extending to all
Brussels maternity wards by 2000. The screened patients,
mostly coming from French speaking Africa, tended to be
concentrated in the French speaking part of Belgium, par-
ticularly in Brussels and Lie`ge. In 2001, universal neonatal
screening was proposed in Wallonia, the French speaking
Belgium region. It was performed regardless of patient’s
insurance cover, country of origin, or immigration status
(legal or not). Since 2003, it includes neonates born under
the care of all maternity facilities in Brussels and two other
maternity facilities in the Wallonian region.
Umbilical cord blood samples were screened initially
using an isoelectric focusing technique (Perkin Elmer Life
Sciences, Zaventem, Belgium), and from 2008 using a capil-
lary electrophoresis technique (Sebia Benelux, Vilvoorde,
Belgium). Heel prick samples were screened by tandem
mass spectrometry.9 If a hemoglobin variant was detected,
further analysis was performed using
high-performance liquid chromatography (BioRad,
Hercules, California, USA) or DNA analysis. Children
presenting with SCD were referred to a specialized center
for clinical management. Patients with SCD identiﬁed,
either through screening or diagnosis following their ﬁrst
SCD-clinical event, were seen and followed regularly in the
participating centers according to the policy of each center.
All SCD patients received a prescription for recommended
oral antibiotic prophylaxis to at least age ﬁve. The usual
nationally recommended immunization schedule was pro-
vided, including conjugate vaccines against Haemophilus
inﬂuenzae type b (four doses) since 1994, and
Streptococcus pneumoniae (three doses) since 2004. From
1999 one center used transcranial doppler ultrasonography
for SCD patient follow-up, and this technique is now being
extended to all centers. Disease modifying therapies such as
Hydroxyurea (HU),10–12 chronic transfusion, and hemato-
poietic stem cell transplantation (HSCT)13–16 were applied
according to each center’s policy, but mostly following the
usual indications that have been detailed in previous inter-
national publications.17–20 HU was mainly prescribed for
patients with recurrent painful episodes and acute chest
syndrome (ACS).
For patients lost to follow-up, last available data were
from the last visit. After HSCT, only vital status was rec-
orded, and cause of death if applicable. The proportion
of patients developing major SCD-related events, the inci-
dence of a ﬁrst major SCD-related event, hospitalization
(number and days), and treatments were analyzed in both
groups. Major SCD-related clinical events were deﬁned
as: ACS, vaso-occlusive crisis (VOC), acute anemia
(Hb< 60 g/L) requiring transfusion, cerebral complication
(stroke or transient ischemic attack), severe infection
(bacteremia, meningitis, pneumonia, osteomyelitis), and
among patients with severe infection, episodes of bacter-
emia (deﬁned as fever associated with altered general
status and identiﬁcation of a pathogen on blood culture).
The most common reasons for hospitalization were acute
pain crisis (dactylitis, VOC, ACS), infections, and acute
anemia episodes requiring transfusion.
Informed consent was obtained from all patients (or
parents/legal guardians). For patients deceased before
2008, data were collected retrospectively (Central Ethics
Committee Approval N: AK/07-11-64/3473). Local
ethics committees approved data collection and registry.
The dataset included the diagnosis (date, method, and
genotype), demographics, SCD-related events, transfu-
sion, hospitalizations, immunization, steady-state bio-
logical parameters, radiological data, the presence of
chronic organ damage (e.g. cerebral vasculopathy, renal
failure), treatments, vital status, and if appropriate, cause
of death. For those lost to follow-up, survival data were
removed from consideration from the date of the last visit.
The study database was locked in December 2012.
Categorical and continuous variables were analysed
with Graphpad Prism software 5.0 (Graphpad
Software Inc, San Diego, USA). Kruskal–Wallis test was
used to compare continuous data of multiple groups, gen-
erating median values. Chi-squared and Fisher’s tests were
used to compare data expressed as proportions. The esti-
mate of survival to remain free of speciﬁc SCD-related
complications was generated for the time to ﬁrst event
in the screened versus the unscreened group. Kaplan–
Meier and the 95% conﬁdence interval (95% CI) were
calculated for all SCD-related complications. Survival
curves of the diﬀerent events were compared by the
log-rank test. A p-value less than 0.05 was considered stat-
istically signiﬁcant. Propensity score analysis was per-
formed to match patients between groups using three
covariates: gender, genotype, and central Africa origin.
The covariate balancing propensity score R package was
used to perform the propensity score, estimating an aver-
age group eﬀect and requiring an exact match, using cov-
ariate balancing, which has been showed to be superior to
traditional logistic regression approaches and boosted
classiﬁcation and regression trees.21 An absolute standar-
dized diﬀerence less than 10–15% was considered to
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support the assumption of balance between the groups
because it is not aﬀected by the sample size, unlike
p-values, and it may be used to compare the relative
balance of variables measured in diﬀerent units.22
The percentages of categorical variables before and after
propensity score are presented. For time-to-event ana-
lyses, application of propensity scores using inverse
probability weighting (IPW), rather than matching, strati-
ﬁcation, or adjustment, were used as it produces eﬀect
estimates with minimal bias.23,24 For binary outcomes,
the eﬀect of neonatal screening method on the outcome
is estimated by the regression of the outcome on an indi-
cator variable denoting neonatal screening method assign-
ment and the propensity score (inverse probability of
neonatal screening weighting). For continuous variables,
the eﬀect of the neonatal screening method was estimated
by the linear regression of the outcome on an indicator
variable denoting group assignment; the covariates pre-
sent in the propensity score (inverse probability of
neonatal screening weighting). Bonferroni correction was
applied in all analyses. A p-value less than 0.0083 (0.05/6)
was considered statistically signiﬁcant as six variables
were tested.
Results
Among the 469 patients recorded in the registry, 260 were
born in Belgium, including 167 screened at birth and





Number of patients 167 93
Sex (male) (%) 81 (48.5) 45 (48.4) 1.0
HbSS-HbSb0 (%) 142 (85) 87 (93.5) 0.046
Median age at diagnosis years
(range)
0 1.0 (0.1–15.3) <0.0001
Median age at last follow-up years
(range)
6.1 (1.0–22.1) 10.8 (1.1–41.7) <0.0001
Median follow-up years (range) 6.1 (1.0–22.1) 9.6 (0.4–35.0) <0.0001
Total follow-up (patient-years) 1116 958
Lost to follow-up 6 3 1.0
Death 2 1 1.0
Hospitalization – Number per 100
patient-years (median, range)
0.27 (0–3.41) 0.63 (0–5.74) 0.0006
Hospitalization – Days per 100
patient-years (median, range)
1.25 (0–21.42) 2.82 (0–35.28) <0.0001
469 registered paents 
260 paents  
born in Belgium 
209 paents  
not born in Belgium 
167 paents NSP 
1116 paent-years follow-up 
93 paents no NSP 
958 paent-years follow-up 
Figure 1. Flow chart of the SCD patients born in Belgium.
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93 not screened, accounting for 1116 and 958 patient-
years of follow-up, respectively (Figure 1). Demographic
and follow-up characteristics of both cohorts are summar-
ized in Table 1. As reported previously,7 in the screened
cohort six patients were lost to follow-up and two patients
died (age 1.5 and 2.1 years) during the 1990, before the
complete programme was implemented. In the unscreened
cohort, three patients were lost to follow-up and one died
(age 18.7 years; hemorrhagic stroke). Death rate was simi-
lar in both groups, i.e. 1.2% (0.18 per 100 patient-years)
and 1.1% (0.10 per 100 patient-years), respectively (p¼ 1).
Screened patients were statistically younger at diagnosis
and at last follow-up. They also had a shorter period of
follow-up. Most of the patients have a severe genotype
and the majority of the families originate from Central
African countries (70% from the screened and 77%
from the unscreened cohort), and particularly from the
Democratic Republic of Congo (60%). The unscreened
group had signiﬁcantly higher rate and days of hospital-
ization than the screened group.
Among the 260 patients, 81.5% presented with at least
one major documented SCD-related complication.
Propensity score analyses before and after matching
between screened and unscreened groups on the three cov-
ariates are reported in Table 2. The mean age at ﬁrst ACS,
anemia, cerebral complication, severe infection, or bacter-
emia was not statistically diﬀerent in both groups, while
the mean age at ﬁrst VOC occurred statistically earlier in
the screened cohort (Table 3). The Kaplan–Meier analyses
of ACS, anemia, cerebral complication, bacteremia, and
VOC from both cohorts are detailed in the Figure 2. They
show that the 15-year estimate of survival from diagnosis
without bacteremia was signiﬁcantly higher in the
screened group than the unscreened group (94.47%;
[95% CI, 88.64–97.36%] vs. 83.78% [95% CI, 72.27–
90.42%]), p¼ 0.032 (Figure 2). No screened patients
were diagnosed with a ﬁrst VOC at an older age, but
Kaplan–Meier estimates of survival without VOC from
diagnosis were statistically not diﬀerent in both groups
(41.38% [95% CI, 30.87–51.56%] vs. 37.90% [95% CI,
26.5–49.23%]), p¼ 0.953 (Figure 2). A detected trend to
lower severe infection in the screened group was not sig-
niﬁcant (Figure 2). Incidence of cerebral complications
(transient ischemic attack and stroke) was not statistically
diﬀerent between groups (Table 1). All patients with cere-
bral complication were homozygous for Hb S. The 15-year
estimate of survival from diagnosis without cerebral com-
plication was above 95% in both groups (Figure 2).
Therapeutic intensiﬁcation was applied to 43%
(72/167) of those in the screened group and 83% (77/93)
of those in the unscreened group. The median ages at
therapeutic intensiﬁcation were 3.2 years (0.8–12.4 years)
and 5.1 years (0.7–31.9 years), respectively. HU treatment
was more frequently prescribed in the unscreened group
than the screened group (45% vs. 30%; p¼ 0.015), but
introduced at a younger age in the screened cohort:
2.6 years (range: 0.6–7.9 years) versus 4.5 years (range:
0.7–31.9 years) (p¼ 0.0001). This is still the case when
considering patients with severe genotype. HSCT was per-
formed in 10% of the screened and 30% of unscreened
patients (p¼ 0.0001). Median age at transplantation was
4.9 years (range: 1.1–12.4 years) and 4.55 years (range:
1.1–15.3 years), respectively (p¼ 1). All the HSCT patients
were homozygous for Hb S.
Discussion
Data from Belgium and elsewhere show that, even in
developed countries, SCD patients have higher morbidity
and mortality rates than the general population.5,25–29 Our
Table 2. Patient characteristics by neonatal screening status for propensity-matched patients.















Gender (Male) 48.39% 48.50% 0.23189232 47.65% 47.65% 0
Genotype (SSþ Sb0) 93.55% 85.03% 27.8104564 88.16% 88.16% 0
Central Africa Origin 78.49% 68.86% 22.0048643 72.41% 72.41% 0
Differences between the three chosen covariates included in the propensity score disappeared after covariate balancing propensity score
was run because all absolute standardized differences are equal to 0. Moreover, all patients remain in the sample after propensity.













Acute chest syndrome 1.99 3.87 0.90 2.38 0.0114
Acute anemia 2.29 4.83 1.09 2.16 0.0213
Cerebral complication 0.33 2.03 0.16 1.45 0.4588
Bacteremia 0.56 2.07 0.13 0.75 0.0508
Severe infection 1.04 2.46 0.39 1.19 0.0141
Vaso-occlusive crisis 3.28 5.57 1.21 1.96 0.0034
Weighted means and standard deviations by group, and adjusted p-value of
the group effect from each linear regression. Bonferroni correction was used
to reach the significant level. As there were six comparisons, a p-value less
than 0.0083 (0.05/6) was considered statistically significant.
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Figure 2. (a) 15-year Kaplan–Meier estimate without acute chest syndrome were not different in both groups (65.17% [95% CI, 51.07–
76.13%] vs. 63.57%; 95% CI, 51.03–73.71%], p¼ 0.821). (b) 15-year Kaplan–Meier estimate without anemia were not different in both groups
(36.42%; [95% CI, 19.15–53.95%] vs. 50.66%; 95% CI, 38.72–61.42%], p¼ 0.586). (c) 15-year Kaplan–Meier estimate without cerebral com-
plication were not different in both groups (97.98%; [95% CI, 72.27–99.33%] vs. 96.80%; [95% CI, 89.73–99.03%], p¼ 0.755). (d) 15-year
Kaplan–Meier estimate without bacteremia was significantly higher in the screened group than the unscreened group (94.47% [95% CI, 88.64–
97.36%] vs. 83.78% [95% CI, 72.27–90.42%], p¼ 0.032). (e) 15-year Kaplan–Meier estimate without severe infection were not different in both
groups (80.00% [95% CI, 71.21–86.36%] vs. 65.68% [95% CI, 53.64–75.30%], p¼ 0.054). (f) 15-year Kaplan–Meier estimate without VOC were
not different in both groups (41.38% [95% CI, 30.87–51.56% vs. 37.90%; [95% CI, 26.50–49.23%, p¼ 0.953).
Leˆ et al. 5
data indicate that bacteremia is less frequent in screened
patients, possibly because of systematic antibiotic use,
widespread immunization with conjugated vaccines
against Streptococcus pneumoniae and Haemophilus inﬂu-
enzae type b,3,30,31 or parental education from the time of
diagnosis.25,26 This underlines the importance of compre-
hensive medical follow-up associated with universal neo-
natal screening.25,32 A dedicated nurse is probably also
crucial, to provide information, discuss treatment, and
reinforce contacts with SCD patients and their families.
They also organize annual exams and are a key point of
contact with social workers and educational teams, work
crucial to improve adherence to treatment and empower-
ment of families. Adherence to antibiotic prophylaxis
might be less good in the unscreened cohort because edu-
cation starts later, but the eﬃciency of all other imple-
mented measures could explain why, while the
bacteremia rate is increased, the survival rate is not
aﬀected. The lost to follow-up rate (3.6%, 6/167) in our
neonatal screening programme was similar to that from
the London and Dallas cohorts.26,28 Our screening pro-
gramme death rate (1.2% (2/167); 0.18 per 100 patient-
years) was similar to the London cohort, but inferior to
the rate in the Californian, Dallas, and Brazilian
cohorts.25,28,29 Our more favorable results might be
explained by speciﬁc programmes developed in participat-
ing centers, easy access to medical care for all patients
across the country, and the eﬀort expended on education
of patients and families over many years.
Our unscreened cohort is older and has a longer dur-
ation of follow-up, which might explain why those
patients developed more complications than the screened
cohort. Nevertheless, Kaplan–Meier analysis on the entire
cohort conﬁrmed the clear advantage of the screened
group in the risk of developing bacteremia. A lower hos-
pitalization rate and days were also found in the screened
group. These advantages may be explained by several fac-
tors. Screened patients and their families may be more
concerned by the disease and more prompt to react to
clinical signs due to educational and comprehensive care
eﬀorts implemented earlier. The eﬀective implementation
of antibacterial prophylaxis may also contribute, as may
rapid implementation of HU in screened patients as indi-
cated in recently published guidelines. Importantly, fatal-
ities or bacteremia that occur before the diagnosis of SCD
were not recorded in our database due to our method-
ology, and this might lead to underestimation of the rate
of these complications in the unscreened cohort. Our
results clearly demonstrate the long-term positive impact
of neonatal screening on the risk of developing bacter-
emia, but screened patients have similar adjusted 15-year
overall survival and survival without ACS, acute anemia
cerebrovascular disease, and severe infections to the
unscreened cohort. The reason for the lower hospitaliza-
tion rate in screened patients is not clear. Earlier introduc-
tion of HU might be an explanation, with less complicated
ACS or VOC, but these data were not systematically rec-
orded in the registry as we did not record the number of
speciﬁc events once the ﬁrst had occurred. Our method-
ology does not allow us to compare the incidence of VOC
or ACS over time, expressed as the number of events per
100 patient-years.
This study has several limitations, including the rela-
tively small size of our cohort, and the possibility of
incomplete data in the retrospective part of the study. In
addition, events such as fatal sepsis, VOC, or ACS occur-
ring before adequate diagnosis in the unscreened cohort
are misdiagnosed and missing in the records. The morbid-
ity data are quite convincing in terms of advantages, with
signiﬁcantly lower bacteremia and lower hospitalization
rate and days per 100 patient-years in the screened
patients, so even though our data showed no diﬀerence
in overall survival, the better event-free survival for bac-
teremia is important. Indeed, those infections are poten-
tially associated with a higher co-morbidity (VOC, ACS,
severe anemia requiring transfusion).
Conclusion
In Belgium, neither antenatal nor neonatal screening have
been organized or funded nationally,33 but our results sug-
gest that universal neonatal screening is feasible and
eﬀective to detect SCD and improve SCD patient care in
Belgium, and that children diagnosed with SCD beneﬁt
from comprehensive expert medical care in dedicated cen-
ters. This includes education of patients and parents on
complication prevention, lifestyle, and management of
fever and pain. It requires collaboration among parents
and patients, doctors, nurses and social workers, not only
in case of acute events, but also for prevention, early
detection, and treatment of chronic organ damage, to
enable patients to better control their disease. Integrated
care allows earlier introduction of disease modifying
therapies to reduce morbidity and improve quality of
life, as our data and recent French data32 both show.
SCD screening, either before conception or during the
antenatal/neonatal period, should be extended to the
whole country.
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